Tower Research Capital (TRC)’s Virtus Biotech ETF BBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBP Stock Details BBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-35	Closed	-$1K	–	2703
2017 Q1	$1K	Buy	+35	New	+$1.28K	﹤0.01%	2759
2016 Q4	–	Sell	-70	Closed	-$2K	–	3815
2016 Q3	$2K	Sell	70 -30	-30%	-$926	﹤0.01%	3028
2016 Q2	$3K	Sell	100 -48	-32%	-$1.27K	﹤0.01%	3655
2016 Q1	$4K	Sell	148 -739	-83%	-$18K	﹤0.01%	2852
2015 Q4	$27K	Sell	887 -141	-14%	-$4.27K	﹤0.01%	978
2015 Q3	$28K	Buy	+1,028	New	+$34.7K	﹤0.01%	1445
2015 Q1	–	Sell	-38	Closed	-$1K	–	4397
2014 Q4	$1K	Buy	+38	New	+$994	﹤0.01%	3592

Other funds holding BBP

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Tower Research Capital (TRC)'s BBP Position: Q2 2017 in Review

Tower Research Capital (TRC) sold out of Virtus Biotech ETF (BBP) in Q2 2017, closing a stake of 35 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in BBP in Q4 2014 and held it in 7 quarters. The position peaked at $28K in Q3 2015. 19 funds tracked by Wall St. Rank hold BBP as of Q2 2017.

Tower Research Capital (TRC) reported no remaining Virtus Biotech ETF position as of Q2 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 35 Virtus Biotech ETF shares in Q2 2017, an estimated $1K.
Tower Research Capital (TRC) first reported a position in Virtus Biotech ETF in Q4 2014 and held it in 7 quarters.
Tower Research Capital (TRC)'s Virtus Biotech ETF position peaked at $28K in Q3 2015.
19 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2017, filed 15 Aug 2017.